Дупилумаб при атопическом дерматите: обзор данных и опыт применения

Введение. Атопический дерматит (АтД) – хроническое воспалительное заболевание кожи, существенно влияющее на качество жизни пациентов. Появление таргетной биологической терапии дупилумабом стало важным этапом в лечении среднетяжелого и тяжелого АтД, что подтверждено клиническими исследованиями и данными реальной клинической практики. Цель. Изучить динамику качества жизни у пациентов с АтД, получающих дупилумаб, в реальной клинической практике.

Материалы и методы. Проведен обзор современной литературы, включающей результаты клинических исследований и регистровых данных, а также анализ собственной выборки из 38 пациентов с АтД, получавших терапию дупилумабом. Оценивалась динамика клинических индексов (EASI, SCORAD, VAS) и показатели качества жизни (DLQI – у взрослых и CDLQI – у детей).

Результаты. Возраст пациентов варьировал от 6 до 47 лет (средний – 20 лет), мужчины составили 65,8%. Продолжительность терапии составляла от 2 до 5 лет (в среднем – 3,4 года). На фоне лечения средний индекс EASI снизился с 39,0 до 5,2 (p < 0,0001), SCORAD – с 58,7 до 11,2 (p < 0,0001), VAS – с 7,3 до 2,2 (p < 0,0001). Показатели качества жизни улучшились: DLQI снизился с 25,1 до 2,3, CDLQI – с 21,1 до 2,4 (оба p < 0,00001). Полученные данные согласуются с международными исследованиями (TREATgermany, BioDay, RELIEVE-AD).

Выводы. Дупилумаб демонстрирует высокую эффективность, значимое снижение клинических проявлений и улучшение качества жизни у взрослых и детей с АтД при длительном применении в реальной клинической практике. Сочетание данных рандомизированных исследований и реальной практики подтверждает, что дупилумаб является препаратом выбора и может рассматриваться как оптимальная долгосрочная терапевтическая стратегия для пациентов с АтД.

1. Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):320–329. https://doi.org/10.2340/00015555-3510.

2. Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, Ständer S et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142–152. https://doi.org/10.1111/jdv.15919.

3. Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–456. https://doi.org/10.1016/j.jaad.2018.03.017.

4. Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. https://doi.org/10.1111/bjd.19580.

5. Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. https://doi.org/10.1016/j.jaci.2018.08.022.

6. Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14. https://doi.org/10.1111/cea.13491.

7. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. https://doi.org/10.1016/S0140-6736(17)31191-1.

8. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348. https://doi.org/10.1056/NEJMoa1610020.

9. Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537–1566. https://doi.org/10.1111/jdv.20639.

10. Mortato E, Talamonti M, Paganini C, Belcastro A, Tofani L, Bianchi L, Galluzzo M. Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study. Int J Dermatol. 2025. https://doi.org/10.1111/ijd.17939.

11. Zeidler C, Tsianakas A, Pereira M, Ständer H, Yosipovitch G, Ständer S. Chronic Prurigo of Nodular Type: A Review. Acta Derm Venereol. 2018;98(2):173–179. https://doi.org/10.2340/00015555-2774.

12. Yosipovitch G, Kwatra ShG, Mollanazar N, Ständer S, Satoh T, Laws E et al. 344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2). Br J Derm. 2023;188(Suppl. 2):ljac140.038. https://doi.org/10.1093/bjd/ljac140.038.

13. Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489. https://doi.org/10.1016/j.jaci.2019.08.035.

14. Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023;78(4):1047–1059. https://doi.org/10.1111/all.15561.

15. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. https://doi.org/10.1056/NEJMoa1314768.

16. Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebocontrolled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8.

17. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. https://doi.org/10.1111/bjd.17869.

18. Foley P, Kerdraon YA, Hogden JP, Shumack S, Spelman L, Sebaratnam DF et al. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. Australas J Dermatol. 2022;63(4):421–436. https://doi.org/10.1111/ajd.13924.

19. Wu D, Daniel BS, Lai AJX, Wong N, Lim DKA, Murrell DF et al. Dupilumabassociated ocular manifestations: A review of clinical presentations and management. Surv Ophthalmol. 2022;67(5):1419–1442. https://doi.org/10.1016/j.survophthal.2022.02.002.

20. Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023;78(8):2266–2276. https://doi.org/10.1111/all.15717.

21. Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA et al. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. Br J Dermatol. 2024;191(6):865–885. https://doi.org/10.1093/bjd/ljae344.

22. Chrétien B, Dolladille C, Alexandre J, Fedrizzi S, Lelong-Boulouard V, Lambert JC, Ezine E. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®. Br J Dermatol. 2021;185(2):464–465. https://doi.org/10.1111/bjd.20138.

23. Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management. JAAD Case Rep. 2022;21:14–18. https://doi.org/10.1016/j.jdcr.2021.12.011.

24. Woodbury MJ, Smith JS, Merola JF. Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective. Am J Clin Dermatol. 2023;24(6):859–864. https://doi.org/10.1007/s40257-023-00804-5.

25. Napolitano M, Ruggiero A, Patruno C. Dupilumab-associated inflammatory arthritis: a literature review. Clin Exp Dermatol. 2024;49(4):307–312. https://doi.org/10.1093/ced/llad390.

26. Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study. J Dermatol. 2023;50(7):880–887. https://doi.org/10.1111/1346-8138.16764.

27. Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series. Dermatol Ther. 2019;32(6):e13142. https://doi.org/10.1111/dth.13142.

28. Maronese CA, Valenti M, Moltrasio C, Romagnuolo M, Ferrucci SM, Gilliet M et al. Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options. J Invest Dermatol. 2024;144(11):2364–2376. https://doi.org/10.1016/j.jid.2024.05.015.

29. Grolleau C, Calugareanu A, Demouche S, Nosbaum A, Staumont-Sallé D, Aubert H et al. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol. 2023;143(5):711–721. https://doi.org/10.1016/j.jid.2022.10.015.

30. Trave I, Salvi I, Burlando M, Cozzani E, Parodi A. “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature. J Clin Med. 2023;12(19):6291. https://doi.org/10.3390/jcm12196291.

31. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021;84(5):1339–1347. https://doi.org/10.1016/j.jaad.2021.01.012.

32. Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15(1):2839. https://doi.org/10.1038/s41467-024-46540-0.

33. Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M et al. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol. 2019;20(3):443–456. https://doi.org/10.1007/s40257-019-00445-7.

34. Blauvelt A, Wollenberg A, Eichenfield LF, Zhang H, Sierka D, Khokhar FA et al. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab. Adv Ther. 2023;40(1):367–380. https://doi.org/10.1007/s12325-022-02322-y.

35. Pera V, Brusselle GG, Riemann S, Kors JA, Van Mulligen EM, Parry R et al. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1276340. https://doi.org/10.3389/fphar.2023.1276340.

36. Gill K, Xu J, Kozera E, Stewart T, Flora A, Frew JW. Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility. Br J Dermatol. 2023;188(2):294–295. https://doi.org/10.1093/bjd/ljac060.

37. Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep. 2008;10(2):105–110. https://doi.org/10.1007/s11908-008-0019-6.

38. Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ. The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study. J Eur Acad Dermatol Venereol. 2025. https://doi.org/10.1111/jdv.20724.

39. Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF et al. Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study. Pediatr Dermatol. 2025;42(2):251–258. https://doi.org/10.1111/pde.15781.

40. Johansson EK, Ivert LU, Bradley B, Lundqvist M, Bradley M. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. BMC Dermatol. 2020;20(1):8. https://doi.org/10.1186/s12895-020-00103-0.

41. Nicolosi S, Barei F, Romagnuolo M, Fumagalli S, Marzano AV, Ferrucci SM. Does Body Mass Index Impact the Clinical Response to Dupilumab Therapy in Atopic Dermatitis? A Monocentric Study of 170 Patients. J Clin Med. 2024;13(15):4559. https://doi.org/10.3390/jcm13154559.

42. Tayefi M, Svedbom A, Ivert L, Lundqvist M, Ruas J, Bradley M, Johansson E. Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis. Acta Derm Venereol. 2024;104:adv40796. https://doi.org/10.2340/actadv.v104.40796.

43. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56. https://doi.org/10.1001/jamadermatol.2019.3336.

44. Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019.

45. Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. J Cutan Med Surg. 2023;27(4):358–367. https://doi.org/10.1177/12034754231188444.

46. Treudler R, Delaroque N, Puder M, Simon JC, Szardenings M. Dupilumabinduced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2021;35(1):e30–e32. https://doi.org/10.1111/jdv.16782.

47. Jung JH, Shapero M, Kaplan B. Nonirritating skin test concentrations and a case of serum sickness to dupilumab. J Allergy Clin Immunol Pract. 2023;11(4):1314–1316. https://doi.org/10.1016/j.jaip.2022.12.036.

48. Ludriksone L, Elsner P, Schliemann S. Acquired hypersensitivity to dupilumab: first case report. J Eur Acad Dermatol Venereol. 2019;33(12):e482–e483. https://doi.org/10.1111/jdv.15807.

49. Preuß SL, Bieber K, Vorobyev A, Recke A, Moderegger EL, Zirpel H et al. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study. J Eur Acad Dermatol Venereol. 2025;39(9):1576–1587. https://doi.org/10.1111/jdv.20670.

50. Gregoriou S, Routsi E, Koumprentziotis IA, Papapanou M, Stratigos A. Dupilumab use for atopic dermatitis during pregnancy: A systematic review. J Eur Acad Dermatol Venereol. 2025;39(9):e750–e755. https://doi.org/10.1111/jdv.20570.

51. Vestergaard C, Deleuran M. Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy. J Eur Acad Dermatol Venereol. 2025;39(9):1527–1528. https://doi.org/10.1111/jdv.20832.

52. Wu H, Zhu J, Yang N, Ji X, Li Z, Zhou Y et al. Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. J Dtsch Dermatol Ges. 2025;23(6):702–710. https://doi.org/10.1111/ddg.15688.

53. Peters AS, Kellberger J, Vogelberg C, Dressel H, Windstetter D, Weinmayr G et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J Allergy Clin Immunol. 2010;126(3):590–5.e53. https://doi.org/10.1016/j.jaci.2010.06.020.

54. Vakharia PP, Silverberg JI. Adult-Onset Atopic Dermatitis: Characteristics and Management. Am J Clin Dermatol. 2019;20(6):771–779. https://doi.org/10.1007/s40257-019-00453-7.

55. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–1138. https://doi.org/10.1016/j.jaci.2013.08.031.

56. Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol. 2022;23(4):433–447. https://doi.org/10.1007/s40257-02200679-y.

57. Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderateto-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365–383. https://doi.org/10.1007/s40257-022-00683-2.

58. Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324–338. https://doi.org/10.1007/s12016-021-08880-3.

59. Bakker DS, van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM et al. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. J Invest Dermatol. 2021;141(8):1943–1953. https://doi.org/10.1016/j.jid.2021.01.022.

60. Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13688. https://doi.org/10.1111/cts.13688.

61. Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P et al. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol. 2020;140(1):191–202. https://doi.org/10.1016/j.jid.2019.05.024.

62. Greenzaid JD, Chan LJ, Chandani BM, Kiritsis NR, Feldman SR. Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. Expert Opin Investig Drugs. 2024;33(4):415–430. https://doi.org/10.1080/13543784.2024.2326625.

63. Bangert C, Rindler K, Krausgruber T, Alkon N, Thaler FM, Kurz H et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Sci Immunol. 2021;6(55):eabe2749. https://doi.org/10.1126/sciimmunol.abe2749.

64. Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148–163. https://doi.org/10.1016/j.jaci.2021.01.001.

65. Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. https://doi.org/10.1016/S0140-6736(22)01199-0.

66. Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Updated Review on Treatment of Atopic Dermatitis. J Investig Allergol Clin Immunol. 2023;33(3):158–167. https://doi.org/10.18176/jiaci.0906.

67. Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2558–2568. https://doi.org/10.1111/jdv.19391.

68. Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, Perez B, Elosua M, Munera-Campos C et al. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results. J Investig Allergol Clin Immunol. 2023;33(3):211–213. https://doi.org/10.18176/jiaci.0831.

69. Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101–1112. https://doi.org/10.1056/NEJMoa2019380.

70. Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9(6):e16704. https://doi.org/10.1016/j.heliyon.2023.e16704.

71. Porter E, O’Connor C, Murphy M. Re-engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis-A mixed methods study. Skin Health Dis. 2024;4(4):e372. https://doi.org/10.1002/ski2.372.

72. Stölzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol. 2022;187(6):1022–1024. https://doi.org/10.1111/bjd.21794.

73. Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S et al. Fiveyear real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors. J Dermatolog Treat. 2024;35(1):2404718. https://doi.org/10.1080/09546634.2024.2404718.

74. Kimball AB, Delevry D, Yang M, Chuang CC, Wang Z, Bégo-Le-Bagousse G et al. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatol Ther. 2023;13(9):2107–2120. https://doi.org/10.1007/s13555-023-00965-5.

75. Sun Y, Liu H, Gao Y, Sang H, Kong Q. Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025;16:1587977. https://doi.org/10.3389/fphar.2025.1587977.